Top

Published in:

01-12-2021 | Hepatocellular Carcinoma | Primary research

Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma

Authors: Yanan Peng, Chang Liu, Mengting Li, Wenjie Li, Mengna Zhang, Xiang Jiang, Ying Chang, Lan Liu, Fan Wang, Qiu Zhao

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most prevalent and inflammation-associated cancers. The tumor microenvironment (TME) plays an essential role in HCC development and metastasis, leading to poor prognosis. The overall TME immune cells infiltration characterizations mediated by immune-related genes (IRGs) remain unclear. In this study, we aimed to investigate whether immune-related genes could be indicators for the prognosis of HCC patients and TME cell infiltration characterization as well as responses to immunotherapy.

Methods

We obtained differentially expressed immune-related genes (DE IRGs) between normal liver tissues and liver cancer tissues from The Cancer Genome Atlas (TCGA) database. To identify the prognostic genes and establish an immune risk signature, we performed univariable Cox regression survival analysis and the Least Absolute Shrinkage and Selector Operation (LASSO) regression based on the DE IRGs by robust rank aggregation method. Cox regression analysis was used to identify independent prognostic factors in HCC. We estimated the immune cell infiltration in TME via CIBERSORT and immunotherapy response through TIDE algorithm.

Results

We constructed an immune signature and validated its predictive capability. The immune signature included 7 differentially expressed IRGs: BIRC5, CACYBP, NR0B1, RAET1E, S100A8, SPINK5, and SPP1. The univariate and multivariate cox analysis showed that the 7-IRGs signature was a robust independent prognostic factor in the overall survival of HCC patients. The 7-IRG signature was associated with some clinical features, including gender, vascular invasion, histological grade, clinical stage, T stage. We also found that the 7-IRG signature could reflect the infiltration characterization of different immunocytes in the tumor microenvironment (TME) and had a good correlation with immune checkpoint molecules, revealing that the poor prognosis might be partly due to immunosuppressive TME. The Tumour Immune Dysfunction and Exclusion (TIDE) analysis data showed that the 7-IRG signature had great potential for indicating the immunotherapy response in HCC patients. The mutation analysis demonstrated a significant difference in the tumor mutation burden (TMB) between the high- and low-risk groups, partially explaining this signature's predictive value.

Conclusion

In a word, we constructed and validated a novel, immune-related prognostic signature for HCC patients. This signature could effectively indicate HCC patients' survival and immunotherapy response. And it might act as potential immunotherapeutic targets for HCC patients.

Available only for authorised users

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA. 2020;70:7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-386. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

Heimbach J, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80. https://doi.org/10.1002/hep.29086.CrossRefPubMed

Kuhlmann J, Blum H. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol. 2013;29:324–8. https://doi.org/10.1097/MOG.0b013e32835d9dea.CrossRefPubMed

Personeni N, Pressiani T, Rimassa L. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. Future Oncol. 2019;15:2449–62. https://doi.org/10.2217/fon-2019-0026.CrossRefPubMed

Finn RS, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology. 2018;67:422–35. https://doi.org/10.1002/hep.29486.CrossRefPubMed

Webster GJ, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000;32:1117–24. https://doi.org/10.1053/jhep.2000.19324.CrossRefPubMed

Kudo M. Scientific rationale for combination immunotherapy of Hepatocellular Carcinoma with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies. Liver Cancer. 2019;8:413–26. https://doi.org/10.1159/000503254.CrossRefPubMedPubMedCentral

Jia L, Gao Y, He Y, Hooper J, Yang P. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. 2020;159:104992. https://doi.org/10.1016/j.phrs.2020.104992.CrossRefPubMed

10.

Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2020. https://doi.org/10.1016/j.pharmthera.2020.107753.CrossRefPubMedPubMedCentral

11.

Barry K, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24:1178–91. https://doi.org/10.1038/s41591-018-0085-8.CrossRefPubMedPubMedCentral

12.

Lambrechts D, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24:1277–89. https://doi.org/10.1038/s41591-018-0096-5.CrossRefPubMed

13.

Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27:39–46. https://doi.org/10.1093/intimm/dxu095.CrossRefPubMed

14.

Lee JH, et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol. 2019;68:23–32. https://doi.org/10.1007/s00262-018-2247-4.CrossRef

15.

Yarchoan M, et al. Recent developments and therapeutic strategies against hepatocellular carcinoma. Cancer Res. 2019;79:4326–30. https://doi.org/10.1158/0008-5472.can-19-0803.CrossRefPubMedPubMedCentral

16.

Zhu AX, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–52. https://doi.org/10.1016/s1470-2045(18)30351-6.CrossRefPubMed

17.

Kambhampati S, et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer. 2019;125:3234–41. https://doi.org/10.1002/cncr.32206.CrossRefPubMed

18.

Song Q, et al. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med. 2019;17:70. https://doi.org/10.1186/s12967-019-1824-4.CrossRefPubMedPubMedCentral

19.

Shen S, et al. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer. EBioMedicine. 2019;40:318–26. https://doi.org/10.1016/j.ebiom.2018.12.054.CrossRefPubMed

20.

Wu J, Zhao Y, Zhang J, Wu Q, Wang W. Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019;8:1596715. https://doi.org/10.1080/2162402x.2019.1596715.CrossRefPubMedPubMedCentral

21.

Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. https://doi.org/10.1186/s12943-017-0712-x.CrossRefPubMedPubMedCentral

22.

Goodman AM, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–608. https://doi.org/10.1158/1535-7163.mct-17-0386.CrossRefPubMedPubMedCentral

23.

Roessler S, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology. 2012;142:957-966.e912. https://doi.org/10.1053/j.gastro.2011.12.039.CrossRefPubMed

24.

Bhattacharya S, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58:234–9. https://doi.org/10.1007/s12026-014-8516-1.CrossRefPubMed

25.

Chen HY, Yu SL, Chen CH, Chang GC, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356:11–20. https://doi.org/10.1056/NEJMoa060096.CrossRefPubMed

26.

Lorent M, Giral M, Foucher Y. Net time-dependent ROC curves: a solution for evaluating the accuracy of a marker to predict disease-related mortality. Stat Med. 2014;33:2379–89. https://doi.org/10.1002/sim.6079.CrossRefPubMed

27.

Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381–97. https://doi.org/10.1002/sim.5958.CrossRefPubMed

28.

Newman A, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–7. https://doi.org/10.1038/nmeth.3337.CrossRefPubMedPubMedCentral

29.

Bense R, et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J Nat Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw192.CrossRefPubMed

30.

Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https://doi.org/10.1038/ncomms3612.CrossRefPubMed

31.

Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550–8. https://doi.org/10.1038/s41591-018-0136-1.CrossRefPubMedPubMedCentral

32.

Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747–56. https://doi.org/10.1101/gr.239244.118.CrossRefPubMedPubMedCentral

33.

Robinson DR, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297–303. https://doi.org/10.1038/nature23306.CrossRefPubMedPubMedCentral

34.

Weichhart T, Säemann MD. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis. 2008. https://doi.org/10.1136/ard.2008.098459.CrossRefPubMed

35.

Jiang G, Shi L, Zheng X, Zhang X, Wu K, et al. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging. 2020. https://doi.org/10.18632/aging.103231.CrossRefPubMedPubMedCentral

36.

Yoo C, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver Int. 2020. https://doi.org/10.1111/liv.14496.CrossRefPubMed

37.

Nishida N, Kudo M. Immune phenotype and immune checkpoint inhibitors for the treatment of human hepatocellular carcinoma. Cancers. 2020. https://doi.org/10.3390/cancers12051274.CrossRefPubMedPubMedCentral

38.

Rizvi S, Wang J, El-Khoueiry A. Liver cancer immunity. Hepatology. 2020. https://doi.org/10.1002/hep.31416.CrossRefPubMed

39.

Nukui T, et al. S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. J Cell Biochem. 2008;104:453–64. https://doi.org/10.1002/jcb.21639.CrossRefPubMed

40.

Németh J, et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology. 2009;50:1251–62. https://doi.org/10.1002/hep.23099.CrossRefPubMed

41.

De Ponti A, et al. A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Lett. 2015;369:396–404. https://doi.org/10.1016/j.canlet.2015.09.005.CrossRefPubMed

42.

Lian YF, et al. CACYBP Enhances Cytoplasmic Retention of P27(Kip1) to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation. Theranostics. 2019;9:8392–408. https://doi.org/10.7150/thno.36838.CrossRefPubMedPubMedCentral

43.

Cao W, et al. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J Biol Chem. 2007;282:18922–8. https://doi.org/10.1074/jbc.M702504200.CrossRefPubMed

44.

Lamort A, Giopanou I, Psallidas I, Stathopoulos G. Osteopontin as a link between inflammation and cancer: the thorax in the spotlight. Cells. 2019. https://doi.org/10.3390/cells8080815.CrossRefPubMedPubMedCentral

45.

Wang J, Hao F, Fei X, Chen Y. SPP1 functions as an enhancer of cell growth in hepatocellular carcinoma targeted by miR-181c. Am J Transl Res. 2019;11:6924–37.PubMedPubMedCentral

46.

Hegde P, Karanikas V, Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res. 2016;22:1865–74. https://doi.org/10.1158/1078-0432.ccr-15-1507.CrossRefPubMed

47.

Ghiringhelli F, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005;202:1075–85. https://doi.org/10.1084/jem.20051511.CrossRefPubMedPubMedCentral

48.

Chen M, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA. 2005;102:419–24. https://doi.org/10.1073/pnas.0408197102.CrossRefPubMed

49.

Zhou SL, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology. 2016;150:1646–58. https://doi.org/10.1053/j.gastro.2016.02.040.CrossRefPubMed

50.

Peng ZP, et al. Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma. J Hepatol. 2020. https://doi.org/10.1016/j.jhep.2020.05.004.CrossRefPubMed

51.

Zhao X, et al. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization. Exp Cell Res. 2020;391:111979. https://doi.org/10.1016/j.yexcr.2020.111979.CrossRefPubMed

52.

Wang D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett. 2019;452:244–53. https://doi.org/10.1016/j.canlet.2019.03.040.CrossRefPubMed

53.

Mamrot J, Balachandran S, Steele EJ, Lindley RA. Molecular model linking Th2 polarized M2 tumour-associated macrophages with deaminase-mediated cancer progression mutation signatures. Scand J Immunol. 2019;89:e12760. https://doi.org/10.1111/sji.12760.CrossRefPubMedPubMedCentral

54.

Banchereau J, et al. Immunobiology of dendritic cells. Ann Rev Immunol. 2000;18:767–811. https://doi.org/10.1146/annurev.immunol.18.1.767.CrossRef

55.

Palucka K. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–77. https://doi.org/10.1038/nrc3258.CrossRefPubMedPubMedCentral

56.

Zhou ZJ, et al. Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection. Cancer Immunol Immunother. 2019;68:1223–33. https://doi.org/10.1007/s00262-019-02355-3.CrossRefPubMed

57.

Greenwald R, Freeman G, Sharpe A. The B7 family revisited. Annu Rev Immunol. 2005;23:515–48. https://doi.org/10.1146/annurev.immunol.23.021704.115611.CrossRefPubMed

58.

Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212–8. https://doi.org/10.1038/ni.2762.CrossRefPubMed

59.

Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428–33. https://doi.org/10.1126/science.aaf1292.CrossRefPubMedPubMedCentral

60.

He G, Zhang H, Zhou J, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:141. https://doi.org/10.1186/s13046-015-0256-0.CrossRefPubMedPubMedCentral

61.

Cao D, Chen MK, Zhang QF, et al. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. Aging. 2020. https://doi.org/10.18632/aging.103395.CrossRefPubMedPubMedCentral

62.

Carone C, Olivani A, et al. Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence. Liver Cancer. 2018;7:277–94. https://doi.org/10.1159/000486764.CrossRefPubMedPubMedCentral

63.

Dong LY, Zhou WZ, Ni JW, et al. Identifying the optimal gene and gene set in hepatocellular carcinoma based on differential expression and differential co-expression algorithm. Oncology Reports. 2017;37:1066–74. https://doi.org/10.3892/or.2016.5333.CrossRefPubMed

64.

Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 2018;10:93. https://doi.org/10.1186/s13073-018-0605-7.CrossRefPubMedPubMedCentral

65.

Steuer CE, Ramalingam SS. Tumor mutation burden: leading immunotherapy to the era of precision medicine? J Clin Oncol. 2018;36:631–2. https://doi.org/10.1200/jco.2017.76.8770.CrossRefPubMed

66.

Samstein RM, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–6. https://doi.org/10.1038/s41588-018-0312-8.CrossRefPubMedPubMedCentral

67.

Cai H, et al. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. J Surg Oncol. 2020;121:1007–14. https://doi.org/10.1002/jso.25859.CrossRefPubMed

68.

Mauriello A, et al. High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. Cancers (Basel). 2019. https://doi.org/10.3390/cancers11121824.CrossRef

Title: Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma
Authors: Yanan Peng
Chang Liu
Mengting Li
Wenjie Li
Mengna Zhang
Xiang Jiang
Ying Chang
Lan Liu
Fan Wang
Qiu Zhao
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Checkpoint Inhibitors
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-01792-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

LINC00115 promotes stemness and inhibits apoptosis of ovarian cancer stem cells by upregulating SOX9 and inhibiting the Wnt/β-catenin pathway through competitively binding to microRNA-30a

CEBPG promotes acute myeloid leukemia progression by enhancing EIF4EBP1

Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer

WD40 repeat 43 mediates cell survival, proliferation, migration and invasion via vimentin in colorectal cancer

Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in laryngeal squamous cell cancer

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer